Cargando…
Beyond CAR T-Cell Therapy: Continued Monitoring and Management of Complications
Chimeric antigen receptor (CAR) T-cell therapy has recently emerged as a groundbreaking treatment for CD19-expressing hematologic malignancies and received rapid approval by the U.S. Food & Drug Administration. Tisagenlecleucel and axicabtagene ciloleucel are now widely available at CAR T-cell t...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Harborside Press LLC
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7848815/ https://www.ncbi.nlm.nih.gov/pubmed/33532115 http://dx.doi.org/10.6004/jadpro.2020.11.2.4 |